1154 related articles for article (PubMed ID: 32436290)
1. EAACI Allergen Immunotherapy User's Guide.
Alvaro-Lozano M; Akdis CA; Akdis M; Alviani C; Angier E; Arasi S; Arzt-Gradwohl L; Barber D; Bazire R; Cavkaytar O; Comberiati P; Dramburg S; Durham SR; Eifan AO; Forchert L; Halken S; Kirtland M; Kucuksezer UC; Layhadi JA; Matricardi PM; Muraro A; Ozdemir C; Pajno GB; Pfaar O; Potapova E; Riggioni C; Roberts G; Rodríguez Del Río P; Shamji MH; Sturm GJ; Vazquez-Ortiz M
Pediatr Allergy Immunol; 2020 May; 31 Suppl 25(Suppl 25):1-101. PubMed ID: 32436290
[TBL] [Abstract][Full Text] [Related]
2. Allergen extracts for immunotherapy: to mix or not to mix?
Nony E; Martelet A; Jain K; Moingeon P
Expert Rev Clin Pharmacol; 2016; 9(3):401-8. PubMed ID: 26652799
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
4. T-cell responses during allergen-specific immunotherapy.
Maggi E; Vultaggio A; Matucci A
Curr Opin Allergy Clin Immunol; 2012 Feb; 12(1):1-6. PubMed ID: 22157159
[TBL] [Abstract][Full Text] [Related]
5. Allergen immunotherapy and asthma.
Tosca MA; Olcese R; Licari A; Ciprandi G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():46-48. PubMed ID: 32017211
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Aeroallergen Immunotherapy: Subcutaneous Immunotherapy and Sublingual Immunotherapy.
Ozdemir C; Kucuksezer UC; Akdis M; Akdis CA
Immunol Allergy Clin North Am; 2016 Feb; 36(1):71-86. PubMed ID: 26617228
[TBL] [Abstract][Full Text] [Related]
7. Allergen Immunotherapy in children with respiratory allergic diseases.
Arasi S; Pajno GB; Panasiti I; Sandoval M; Alvaro-Lozano M
Minerva Pediatr; 2020 Oct; 72(5):343-357. PubMed ID: 32731732
[TBL] [Abstract][Full Text] [Related]
8. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
Richards JR; Stumpf JL
Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
[TBL] [Abstract][Full Text] [Related]
9. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair).
Bahceciler NN; Babayigit Hocaoglu A; Galip N
Expert Rev Vaccines; 2014 Dec; 13(12):1427-38. PubMed ID: 25345538
[TBL] [Abstract][Full Text] [Related]
10. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines.
Mascarell L; Van Overtvelt L; Moingeon P
Immunol Allergy Clin North Am; 2006 May; 26(2):283-306, vii-viii. PubMed ID: 16701145
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sublingual immunotherapy tablets in dust mite and pollen allergy.
Bisyuk Y; DuBuske I; DuBuske LM
Allergy Asthma Proc; 2021 Jan; 42(1):36-42. PubMed ID: 33404387
[TBL] [Abstract][Full Text] [Related]
12. GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma.
Zuberbier T; Bachert C; Bousquet PJ; Passalacqua G; Walter Canonica G; Merk H; Worm M; Wahn U; Bousquet J
Allergy; 2010 Dec; 65(12):1525-30. PubMed ID: 21039596
[TBL] [Abstract][Full Text] [Related]
13. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
14. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation].
Kleine-Tebbe J; Ackermann-Simon J; Hanf G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):343-50. PubMed ID: 22373847
[TBL] [Abstract][Full Text] [Related]
15. [New administration routes for immunotherapy].
Martorell Aragonés A
Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
[TBL] [Abstract][Full Text] [Related]
16. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
17. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
[TBL] [Abstract][Full Text] [Related]
18. Allergen immunotherapy: an updated review of safety.
James C; Bernstein DI
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):55-59. PubMed ID: 27906697
[TBL] [Abstract][Full Text] [Related]
19. House dust mite-specific immunotherapy alters the natural course of atopic march.
Tang RB
J Chin Med Assoc; 2020 Feb; 83(2):109-112. PubMed ID: 32015265
[TBL] [Abstract][Full Text] [Related]
20. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation.
O'Hehir RE; Sandrini A; Anderson GP; Rolland JM
Curr Med Chem; 2007; 14(21):2235-44. PubMed ID: 17896972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
